Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells.
Mi HeBhavesh SoniPetra C SchwalieTamara HüsserCaroline WaltzingerDuvini De SilvaYlva PrinzLaura KrümpelmannSamuele CalabroInes MatosChristine TrumpfhellerMarina BacacPablo UmañaMitchell P LevesqueReinhard DummerMaries van den BroekStephan GasserPublished in: Journal for immunotherapy of cancer (2022)
Our data suggest that cord blood-derived and blood-derived cDCs are a good surrogate to study treatment responses in human tumor cDCs. While most cDCs in human tumors display a non-activated phenotype, TL8-506 combinations drive human tumor cDCs towards an immunostimulatory phenotype associated with Th1 responses on stimulation. Hence, TL8-506-based combinations may be promising candidates to initiate or boost antitumor responses in patients with cancer.